Galapagos presents GLPG0634 at EULAR poster session

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos presents GLPG0634 at EULAR poster session

MECHELEN, BELGIUM--(Marketwired - Jun 13, 2013) -

Posters now available online at www.glpg.com Q&A session with Galapagos CSO today at 15.00 CET/9 AM EDT/6 AM PT, call numbers for the teleconference call: US 480-629-9645, Toll-free 877-941-60; Belgium 2290-1608, Toll-free 0800-50747; Netherlands 20 794 8504, Toll-free 0800-265-8528

Galapagos NV ( EURONEXT BRUSSELS : GLPG ) is presenting three posters on its selective JAK1 inhibitor GLPG0634 at the European League Against Rheumatism (EULAR) Annual Congress taking place this week in Madrid, Spain. The posters are available online at www.glpg.com .

Chief Scientific Officer Dr Piet Wigerinck will answer questions about the posters in a teleconference call at 15.00 CET/9 am EDT/6 am PT, call numbers US 480-629-9645, Toll-free 877-941-60; Belgium 2290-1608, Toll-free 0800-50747; Netherlands 20 794 8504, Toll-free 0800-265-8528. A recording of the teleconference call will be archived on Galapagos' website.

Following is an overview of the posters, with key conclusions:

Safety and efficacy of GLPG0634, a selective JAK1 inhibitor, in patients with rheumatoid arthritis: results of a 4-week Phase IIA dose ranging, multi-center trial

Selective inhibition of JAK1 by once-daily dosing of GLPG0634 from 75 - 300 mg was well tolerated and efficacious in this 4-week study. A favourable safety profile was observed, with an absence of the typical findings reported for other JAK inhibitors. GLPG0634 caused no anemia, no overall change to LDL or ALT, and no neutropenia. Regarding efficacy, a dose trend for improvement in RA disease parameters was found: 30 mg QD was sub-optimal, while doses of 75, 150 and 300 mg showed promising efficacy, with similar response rates in CRP, TJC, SJC and DAS28.

An imbalance in baseline characteristics of two patient groups may have influenced the study outcome:

· the placebo group showed a relatively high response rate correlating with a short history of RA

· the 150 mg group was most severely diseased. The 150 mg group showed a robust response in CRP, TJC, and SJC. However, the 4-week duration of the trial was too short to reach the full potential on patient-reported scores (pain assessment, global assessment, HAQ-DI).

The encouraging short term efficacy and favourable safety profile in this study supports the potential of selective inhibition of JAK1 as a future RA treatment option, and confirms data from a previous Proof of Concept study at a 200 mg daily dose.

Once-daily dosing of GLPG0634, a selective JAK1 inhibitor, is supported by its active metabolite

An active and JAK1-selective metabolite supports the activity of GLPG0634. The lower potency of the metabolite is compensated by its high exposure in humans. The long half-life of the metabolite and the resulting high plasma levels when parent GLPG0634 is at trough, provides a lasting effect. Because of the 7-hour half-life of GLPG0634, both BID and QD regimens were studied. However, the metabolite contribution to JAK1 inhibition now provides a potential explanation for the sustained efficacy results observed with once daily dosing of GLPG0634, adding to convenience for patients.

Biological effects of the JAK1 selective inhibitor GLPG0634 on inflammation markers in arthritic mice

Oral administration of the selective JAK1 inhibitor GLPG0634 in arthritic mice demonstrates a selective engagement of the JAK1 target by GLPG0634 in vivo. Progression of established arthritis in the CIA model is blocked by selective inhibition of JAK1. GLPG0634 administration inhibits inflammation and confers structural protection at the level of bone and cartilage in a therapeutic CIA model. A single administration of GLPG0634 is sufficient to block CIA-induced inflammatory signalling.

About candidate drug GLPG0634

GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitor with selectivity for JAK1 developed by Galapagos. JAKs are critical components of signalling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in rheumatoid arthritis patients. JAK inhibitors have shown long-term efficacy in rheumatoid arthritis studies with an early onset of action. GLPG0634 differentiates from other JAK inhibitors in development by specifically targeting JAK1, a strategy which could result in a better efficacy and safety profile. GLPG0634 is a fully proprietary program. Upon successful completion of the Phase 2b studies in RA, AbbVie will license the program and will assume sole responsibility for Phase 3 clinical development and global manufacturing. Furthermore, AbbVie and Galapagos recently announced the initiation of a Phase 2 study with GLPG0634 in Crohn's Disease.

About EULAR

The annual EULAR congresses are a major event in the calendar of world rheumatology. The aim is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, in order to achieve progress in the clinical care of patients with rheumatic diseases. More info at: www.eular.org

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline of four clinical, seven pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.

GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and about to enter Phase 2 studies in Crohn's disease. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD; this program is currently in a Proof of Concept Phase 2 study.

The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: www.glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Galapagos presents GLPG0634 at EULAR poster session: http://hugin.info/133350/R/1709038/566354.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

[HUG#1709038]

CONTACT Galapagos NV Piet Wigerinck CSO Tel: 477 62 7103 Elizabeth Goodwin Director Investor Relations Tel: 6 2291 6240 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 99

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 0

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 52

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 305

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 319

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 24

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 13

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

AEA Private Debt's Strategic Investment in Weller Metalworks

Updated Category News Views 299

Let's cut to the chase: AEA Private Debt is making some serious waves in the middle market with its latest move as the Sole Provider of mezzanine notes for Weller Metalworks' acquisition of DROP Sprockets, Inc. This isn’t just another deal; it’s a calculated step in an increasingly competitive landscape where metal fabrication firms are vying for supremacy. Weller...

Continue Reading
Medication Management Partners Continues to Excel in Senior Care

Updated Category News Views 196

Medication Management Partners Earns Prestigious Recognition In recent news, Medication Management Partners (MMP), a leading long-term care pharmacy, proudly announces its place on the Inc. 5000 list of fastest-growing private companies in America for the seventh consecutive year. This achievement signifies the company’s steady growth and innovative practices in the...

Continue Reading
AlphaGen Unveils Major Expansion Plans for Power Generation

Updated Category News Views 501

AlphaGen's Ambitious 450 MW Power Generation Initiative Alpha Generation, LLC ("AlphaGen"), based in Stamford, Conn., is taking a significant step towards meeting the escalating demand for reliable electric power across the nation. With plans to add approximately 450 megawatts (MW) of additional electric generation at four existing power stations, AlphaGen aims to bolster...

Continue Reading
STAT Secures a Loeb Award for Outstanding Reporting on Opioids

Updated Category News Views 185

STAT Achieves Recognition for Vital Reporting STAT addiction reporter Lev Facher has been honored with a 2025 Loeb Award for his exceptional work in explanatory reporting. This award, regarded as the pinnacle of accomplishment in business and financial journalism, recognizes Facher's six-part series titled "The War on Recovery." The compelling series sheds light on the...

Continue Reading
Investigation into Nomura Holdings, Inc. Sparks Investor Concerns

Updated Category News Views 67

Introduction to the Investigation of Nomura Holdings, Inc. Pomerantz LLP is currently conducting an investigation focused on claims made on behalf of investors of Nomura Holdings, Inc. (NYSE: NMR). The essence of this investigation revolves around whether Nomura and some of its key officers or directors may have engaged in securities fraud or other illicit business...

Continue Reading